Clinical Trials

455 enrolled

Neoplasm Metastasis

NCT03498521 2025-11-19

CUPISCO

529 enrolled 16 charts

Phase 1/2 Active not recruiting

Neoplasms, Unknown Primary

NCT03202940 2025-09-25

A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC

16 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03596866 2025-09-12

ALTA-3

Phase 3 Completed

248 enrolled 20 charts

303 enrolled 31 charts 2 FDA

ALK+ Advanced NSCLC

NCT02075840 2025-07-25

ALEX

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT04341181 2025-07-25

ProTarget

300 enrolled

Phase 2 Active not recruiting

Neoplasms

NCT02314481 2025-05-23

DARWINII

50 enrolled

Carcinoma, Non-Small-Cell Lung, Genomic Instability

NCT02521051 2025-05-13

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Phase 1/2 Terminated

11 enrolled 21 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03445000 2025-04-08

ALERT-lung

Phase 2 Terminated

14 enrolled 14 charts

Carcinoma, Non-Small-Cell Lung

NCT04423185 2025-02-11

PLATFORM Study of Precision Medicine for Rare Tumors

Phase 2 Active not recruiting

770 enrolled

Rare Tumor

NCT03944772 2025-01-30

ORCHARD

247 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04551521 2025-01-08

CRAFT: The NCT-PMO-1602 Phase II Trial

72 enrolled

Neoplasm Metastasis

NCT04632992 2025-01-08

MyTACTIC

Phase NA Not yet recruiting

252 enrolled 27 charts

Advanced Unresectable or Metastatic Solid Malignancy

NCT06709274 2024-11-29

MOTION-NSCLC

342 enrolled

Phase 2 Not yet recruiting

Carcinoma, Non-Small-Cell Lung

NCT06692491 2024-11-18

SPRING

200 enrolled

Rare Tumour

NCT04322890 2024-10-22

PIKACHU

6,000 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05014464 2024-09-20

ATPase

90 enrolled

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT05015010 2024-08-09

ALNEO

33 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

GastrointestinalGenitourinary

673 enrolled 22 charts

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT05525338 2024-05-13

ADAPT ALEC

Phase 4 Recruiting

196 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04817956 2024-02-29

IMPRESS-N

3,000 enrolled

Neoplasm Metastasis

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Phase EARLY_PHASE1 Withdrawn

Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05081674 2023-10-11

BLISS

154 enrolled

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04591431 2023-10-03

ROME

Phase 2 Unknown

400 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

228 enrolled

CNS

Glioblastoma

NCT04644315 2023-08-07

ALpha-T

Phase 2 Terminated

1 enrolled 5 charts

BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Renal Cell, Colonic Diseases, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Melanoma, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Pancreatic Neoplasms, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Salivary Gland Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT03779191 2023-07-06

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

41 enrolled

ALK Gene Rearrangement Positive

NCT05725200 2023-02-21

EVIDENT

40 enrolled

Gastrointestinal

Colorectal Neoplasms

NCT03131206 2021-09-27

A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer

Phase 1/2 Terminated

5 enrolled 8 charts

Head & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms

NCT02013219 2020-04-21

A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)

Phase 1 Completed

52 enrolled